ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Gastrointestinal Cancer

Gastrointestinal Cancer

Advanced colorectal cancer patients with BRAF mutations have markedly worse prognosis than non-mutant patients, according to a large analysis. Post-progression survival in particular is worse among BRAF-mutant patients.

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Patients with metastatic colorectal cancer who engaged in more hours of physical activity at the time of their diagnosis had improvements in both progression-free and overall survival compared with patients who had less physical activity.

Using PET scans during induction chemotherapy for esophageal cancer, researchers were able to assess patient response to treatment and adjust their therapy, leading to an improved rate of pathologic complete response prior to surgery.

Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity.

The regular use of aspirin reduced the risk for pancreatic cancer by almost 50%, according to the results of a Chinese study.

Non-aspirin NSAIDs are more effective than other options for colorectal chemoprevention in individuals with previous colorectal neoplasia, according to a new meta-analysis. Low-dose aspirin, however, is a safer option, and offers the best risk-benefit profile.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.